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to the WHO Commission on Macroeconomics and Health, RLAI is highly cost-
effective (1xGDP per-capita/QALY gained) in patients with a BARR between
63% and 72.5% and cost-effective (3xGDP per-capita /QALY gained) in patients
with a BARR between 35% and 63%. CONCLUSIONS: In all published naturalistic
studies comparing RLAI with oral medication, where the selection of patients to
receive RLAI is left to the physicians, the BARR is greater than 0.71, which
suggest that using RLAI in Mexico with similar criteria of patient selection
would result in a cost-saving strategy.
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OBJECTIVES: Evaluate the effectiveness of quetiapine extended release (XR) versus
quetiapine immediate release (IR) in Mexican Schizophrenic patients from a gov-
ernmental perspective.METHODS: Effective measurements were taken from Meu-
lien=s, et al, 2010 meta-analysis and a systematic review done for this analysis.
Cost-effectiveness and a cost utility analysis were done. Effectiveness measure-
ments were: percentage of patients adherent to treatment, reporting adverse
events (AEs) and with relapse. Disease-specific utility values assigned to each of the
6 schizophrenia disease states, based in the possible combinations of adherence
levels (full, partial, or nonadherence) and the relapse results, have been estimated
by Furiak, 2009 using the Positive and Negative Syndrome Scale, and expert opin-
ion. Costs considered are direct medical care, drug, AEs and relapse treatment.
Analysis used a governmental perspective (Mexican Institute of Social Services
costs), (published May 2012). A Markov model was performed considering a one
year horizon with 3 month cycles simulating schizophrenic Mexican population
with the proposed treatment alternatives. Finally a univariated probabilistic sen-
sitivity analysis was done to validate consistency in the model. RESULTS: The use
of quetiapine XR resulted in more adherent patients with 0.17846 compared with
0.05630 for quetiapine IR; less AEs reported with 0.13716 compared with 0.05462
respectively. In the cost-utility analysis quetiapine XR had an average QALYs of
0.14620 compared to quetiapine IR QALYS of 0.1256. Quetiapine XR generated a cost
saving of USD 508.52 (conversion rate: USD13.14 MxPesos. Average 2012).
CONCLUSIONS: Based on the data from the review and meta-analysis, quetiapine
XR had a similar efficacy and tolerability profile than quetiapine IR but with better
results in effectiveness measures (adherence, adverse events and QALYs). It re-
duces direct treatment costs in Mexican public Institutions with a positive estimate
impact. Based on these, quetiapine XR is a dominant alternative, more effective
and with less costs tan quetiapine IR.
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OBJECTIVES: Schizophrenia is marked by a characteristic interference pattern of
various psychological areas such as perception, ego-function, affectivity and
psychomotricity. Thus, the objective of this economic analysis is the evaluation
of the cost saving potential through the use of Paliperidone Palmitate compared
to Risperidon Depot. METHODS: The pharmaeconomic evaluation was per-
formed using a cost-minimization analysis, in which the above mentioned ther-
apeutic alternatives with equal effectiveness and efficiency are compared based
on the net costs to determine the most cost-effective alternative. The equiva-
lence of the comparators was confirmed in the study of Pandina et al. (2011).
Clinical data derived from this 13-week, double-blind head-to-head study. The
time horizon is 2-years. RESULTS: From the perspective of the health insurance,
the average costs of the therapy algorithm of Paliperidone Palmitate amount to
€5,024.02 for the first year of treatment. A patient treated with Risperidone
Depot is causing costs of €4,750.63. If the patient is treated with Paliperidone
Palmitate as a first-line treatment in the following year, costs of €4,222.32 arise.
In case of a treatment with Risperidone Depot costs amount to €4,594.76 EUR. If
a patient is treated with Paliperidone Palmitate throughout the period under
observation, the discounted total costs for 2-years amount to €9,247.02. Treat-
ment with Risperidone Depot is causing costs of €9,345.40, resulting in a cost
advantage for Paliperidone Palmitate compared to Risperidone Depot of €98.37
for the period of two years. Observing the costs over a time horizon of five years,
a treatment with Paliperidone Palmitate is causing costs in the amount of
20,008.15 EUR. For the same period, a treatment with Risperidone Depot is caus-
ing costs of €20,851.47. CONCLUSIONS: In the treatment of schizophrenia, Pali-
peridone Palmitate is a cost-effective alternative therapy. Additionally, the sen-
sitivity analysis shows that the analysis is, with the exception of doctor
consultations, robust.
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OBJECTIVES: To evaluate the cost-effectiveness of genetic screening for Apolipo-
protein 4 (APOE 4) allele in combination with preventive donepezil treatment in
comparison to the standard of care for Amnestic Mild Cognitive Impairment (AMCI)
patients in Canada.METHODS:We performed a cost-effectiveness analysis using a
Markov model with a societal perspective and a time horizon of 30 years. For each
strategy, we calculated quality-adjusted life years (QALYs) using utilities from the
literature. Costs were also based on the literature, and when appropriate, Ontario
sources. One-way and probabilistic sensitivity analyses were performed. Expected
value of perfect information (EVPI) was conducted to explore the value of future
research. RESULTS: The base case results in our exploratory study suggest com-
bined genetic testing and preventive donepezil treatment resulted in a gain of 0.011
QALYs and an incremental cost of CAD $394 compared to standard of care. The
incremental cost-effectiveness ratio (ICER) for the base case was $35,161 per QALY.
The ICER was sensitive to the effectiveness of donepezil treatment in delaying
progression to AD, and the costs of AD and donepezil. EVPI analysis showed that
additional information on these parameters would be of value. CONCLUSIONS:
Using presently available clinical evidence, this exploratory study illustrates ge-
netic testing combined with preventive donepezil treatment for AMCI patients may
be economically attractive. Since our results were based on a secondary post-hoc
analysis, our study alone is insufficient to warrant recommending APOE genotyp-
ing in AMCI patients. Future research on the effectiveness of preventive donepezil
as a targeted therapy is recommended.
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OBJECTIVES: This evaluation aimed to assess the cost-effectiveness of paliperi-
done palmitate in different lines of therapy for schizophrenia patients compared to
the current patient pathway. METHODS: A Markov model was developed that ex-
amined the use of five different treatment sequences, each involving paliperidone
palmitate at different points in the sequence. Variations in treatment sequences
were assessed to examine their impact on the model’s findings, and were com-
pared with a comparator treatment sequence reflecting current practice. The
model simulated the three main schizophrenic health states of remission, minor
relapse and major relapse. Adherence with medication is also taken into consider-
ation due to its impact on resource use, quality of life and the probability of relapse.
The model adopted a timeline of five years and used a Spanish health care provider
perspective. Drug costs are assumed to be ex factory. RESULTS: The difference in
costs associated with introduction of paliperidone palmitate at different moments
of patient course ranges from an additional €260 when used as a fourth-line ther-
apy to a reduction of €2,217 (i.e. cost saving) when directly used as a second-line
therapy after a course of daily risperidone treatment. Cost savings arose due to
reduced rates of relapse. All five treatment sequences resulted in an increase in
QALYs, ranging from 0.043 QALYs for fourth-line therapy to 0.124 QALYs per pa-
tient for second-line treatment. Second-line treatment was dominant to all other
treatment sequences. Probabilistic sensitivity analysis suggests that the probabil-
ity of paliperidone palmitate being cost-effective as a second-line therapy is 96.8%
at both €30,000 and €45,000 thresholds. One year analysis gave similar results, with
palmitate paliperidone as second-line therapy also dominant to all other treatment
sequences. CONCLUSIONS: Paliperidone palmitate used as second line after a
course of daily risperidone treatment is the dominant alternative when compared
to the other scenarios.
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OBJECTIVES: Schizophrenia is affecting the young adults and amounts to ap-
proximately 80,000 people in Austria, suffering at least one time during their life
from a psychotic episode, which meet the DSM-IV criteria of schizophrenia.
Patients with schizophrenia are at high risk of relapse due to non-adherence of
oral antipsychotic medication. The purpose of this analysis was to estimate the
cost-effectiveness of switching to Paliperidone palmitate after first-line oral
Olanzapine or Risperidone versus an oral treatment algorithm. METHODS: We
developed a Cost-Utility-Model to simulate the consequences of two treatment
algorithms; one with Paliperidone palmitate after treatment failure or stop of
Olanzapine or Risperidone versus a second with oral medication (starting with
Risperidone, Olanzapine, Quetiapine, Haloperidol, Ziprasidone and last-line
Clozapine, followed by no-treatment) over a 5-years horizon. Markov-modeling
techniques were used to estimate incidence of relapse, hospitalization, treat-
ment switch and death. Monte-Carlo simulation accounted for uncertainty. The
model includes eleven health-states. Probabilities were derived from clinical
studies. Direct medical costs from published sources were used and expressed
in 2011 Euro from the payer’s perspective. QALYs and costs were discounted at
5% p.a. RESULTS: Over a 5-year timeframe, costs associated with the use of
Paliperidone palmitate amounts to 28,328.94€ and 3.62 QALYs. Costs associated
with the oral treatment-path are 26,338.23€ and 3.20 QALYs. The incremental-
costs amount to 1,990.71€ per patient and the incremental-cost per QALY gained
was 4,739.79€. The Markov-cohort description shows that 55% of patients who
receive Paliperidone palmitate are still on treatment after 5-years and 24% have
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changed therapy. In the oral treatment group 32% of patients are adherent to
their first-line treatment and 54% have changed treatment. Probabilistic-sensi-
tivity-analyses demonstrated the robustness of the model regarding assump-
tions and input-parameters. CONCLUSIONS: A treatment switch to Paliperidone
palmitate is a cost-effective alternative, improves treatment adherence and
reduces health-care costs in the future and leads to higher quality-of-life.
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OBJECTIVES: Despite of the controversy of antidepressant use during the gesta-
tional period, the reported antidepressant use at any time during pregnancy has
increased. This study aimed to explore antidepressant use behavior (persis-
tence) in low income, insured pregnant women in U.S. METHODS: This retro-
spective study using South Carolina Medicaid claims data (2004-2009) identified
eligible pregnant women (18 years) who were diagnosed with depression and
filled at least two antidepressant prescriptions during pregnancy. Type of anti-
depressant prescribed for pregnant women, length of therapy, antidepressant
use history before pregnancy, and trimester of antidepressant initiation were
measured to describe antidepressant use patterns. Our main outcome measure
was persistence with antidepressant therapy during pregnancy. Failure to per-
sist was defined as having a gap between two consecutive prescriptions of at
least 15 days. A Cox regression model was applied to identify predictors asso-
ciated with the risk for non-persistence with antidepressants in pregnant
women. RESULTS: Of 804 pregnant women meeting the study criteria, 78% took
selective serotonin reuptake inhibitors (SSRIs) during pregnancy, 39% had his-
tory of antidepressant use during 1 year before pregnancy, and less than 40%
initiated therapy during the first trimester. The average length of antidepres-
sant therapy during pregnancy was 114 days. Nearly 55% of women were per-
sistent without a gap ( 15 days) after initiation of antidepressant therapy.
Black women were 33% more likely to be non-persistent with antidepressants
during pregnancy than white women. Women with history of antidepressant
use during 1 year before pregnancy were 44% more likely to be non-persistent
with the therapy. CONCLUSIONS: Persistence with antidepressants was poor
during pregnancy in low income, insured pregnant women. Further studies are
needed to examine associations between persistence with antidepressants dur-
ing pregnancy and maternal and newborn outcomes.
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OBJECTIVES: To give a literature review and assess the health status utility and
productivity of adult patients with attention-deficit/hyperactivity disorder
(ADHD) focusing on measures with outstanding importance for health eco-
nomic analysis. METHODS: PubMed was systematically reviewed for adult
ADHD studies involving the EQ-5D and/or Work Productivity and Activity Im-
pairment (WPAI) questionnaires. A cross sectional survey in an outpatient psy-
chiatry centre was performed and the Clinical Global Impression scale (CGI-S)
was used to categorize patients by severity. RESULTS: While several studies
assessed the impact of ADHD in childhood only one (Patient 2011;4(4):247-57)
dealt with EQ-5D in adult patients and none applied WPAI. In our survey, forty-
four patients (males 79.5%) were involved with mean (SD) age of 30.0 (9.9) years
and disease duration of 7.6 (6.6) years. Thirty-three (75%) were singles, 9 (20.5%)
married (20.5%), 2 (4.5%) divorced and 9 (20.5%) had children. Highest educa-
tional level was primary, secondary school and university at 5 (11.4%), 22 (50.0%)
and 17 (38.7%) cases, respectively. Twenty-nine (65.9%) were taking medication
for ADHD, seven (15.9%) needed accompanying person when travelling for
health care. Injury requiring medical care occurred at 6 (13.6%) patients, 4 re-
lated to ADHD by self-report. Usual activities, pain/discomfort and anxiety/
depression were the most affected EQ-5D dimensions (moderate problem:
52.3%, 47.7%, 54.5%) and the EQ-5D score (mean 0.747, SD 0.280) was signifi-
cantly lower than the age-matched population norm (p0.05). Utility in mild
(CGI-S3) and moderate (CGI-S4) health state was 0.799 and 0.706, respec-
tively. Twenty-three (52.3%) patients were working, 17 (38.6%) were students
and 4 (9.1%) unemployed. WPAI results were as follows, mean (SD): absenteeism
0.1 (0.3)%, presenteeism 33.0 (26.2)%, overall work impairment 16.9 (22.8)%, ac-
tivity impairment 39.5 (28.7)%. CONCLUSIONS: Health status utility and produc-
tivity in adult ADHD is underexplored. Our study suggests that impaired every-
day activities and preseenteism are considerable and deserve further research.
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OBJECTIVES: To assess preferences, using the time trade-off (TTO), regarding fre-
quencies of having to go for a doctor’s visit to receive pharmacological injections
for the treatment of schizophrenia.METHODS:A survey was conducted in Sweden;
respondents including 259 patients with a serious mental disorder, 263 relatives of
individuals suffering from a serious mental disorder, and 528 people sampled from
the general population were recruited for the purpose of this study. A time trade-
off (TTO) study design was used to elicit the utility of decreasing the frequency of
necessary doctor visits. Average utilities were calculated for each health state for
each respondent group. The marginal disutility of an additional yearly visit to the
doctor was estimated using a standard OLS regression with an intercept. Bootstrap-
ping was utilized to compute 95% confidence intervals around utilities and mar-
ginal disutilities. RESULTS: The marginal disutility of an additional doctor visit was
found to be 0.0041 for patients, 0.0022 for relatives, 0.0017 for the general popula-
tion and 0.0022 for an average respondent. For an average respondent across all
groups, this corresponded to an additional utility of 0.031 between having to visit
the doctor for an injection once a month versus every other week and 0.048 be-
tween having to visit the doctor for an injection once every 3 months versus every
other week. CONCLUSIONS: The results are suggestive of a general trend of in-
creased reported disutility for a higher number of doctor visits for an injection per
year across all respondent groups.
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OBJECTIVES: To systematically identify and review published evidence on health-
state utility weights in paediatric and adolescent ADHD.METHODS:Utility weights
were identified as part of a wider systematic review, which was performed to
identify input parameter values for an economic model in ADHD. PubMed, EM-
BASE, Cochrane National Health Service’s Economic Evaluation Database, EconLit,
and Health Economic Evaluations Database were searched from 1960 to May 2011.
The review focused on articles reporting utility weights in ADHD by level of treat-
ment response. RESULTS: A total of 1,648 unique titles and abstracts were re-
trieved; 1,630 records were excluded upon title (or abstract) review and 12 upon
full-text review. The review included 6 studies reporting utilities by level of re-
sponse, 2 of which further stratified utilities by treatment type. One study reported
utilities for 4 health states (‘normal’, ‘borderline to mildly ill’, ‘moderately to mark-
edly ill’, and ‘severely ill’). One study used the EQ-5D instrument completed by
parents; 2 assessed parents’ preferences using standard gamble; 1 used statistical
mapping (for responder and nonresponder states) and time trade-off (TTO) inter-
views and visual analogue scales (for 4 disease-severity health states); 1 calculated
scores from other utility studies; and 1 did not report methods explicitly. Utilities
for responders ranged between 0.98 and 0.80; utilities for non-responders ranged
between 0.93 and 0.70. TTO-derived utilities for the 4 health states were rated by
members of the general public and ranged from 0.839 (’normal’) to 0.444 (’severely
ill’). The review assessed the methodological compliance of each included study
with NICE Reference Case. CONCLUSIONS: Our review identified utility estimates
potentially suitable for use in ADHD economic evaluations. Appropriateness of
these for inclusion in a particular analysis needs to be assessed in terms of the
modelled heath states and the clinical outcomes used to define these.
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OBJECTIVES: To validate the clinically useful depression outcome scale (CUDOS)
for evaluating the severity of depressive symptoms in patients with major depres-
sive disorder (MDD) attending a Primary Care Service. METHODS: An epidemiolog-
ical, cross-sectional, multicentre study was conducted including adult patients
diagnosed as MDD according to the DSM-IV TR during the last 3 months. The
following instruments were applied: Primary Care Evaluation of Mental Disorders
(PRIME-MD), Hamilton Rating Scale for Depression (HAMD-17), CUDOS, Social and
Occupational Functioning Assessment Scale (SOFAS), SF-36 (Physical –PCS- and
Mental –MCS- Component Summaries) and the Clinical global Impression for Se-
verity of Illness (CGI-SI). CUDOS feasibility, internal consistency (Cronbach=s ),
convergent validity (Spearman correlation with SOFAS, HAMD-17 and SF-36) and
discriminant validity (differences in CUDOS values according to HAMD-17 classifi-
cation of severity and the CGI-SI: Kruskal-Wallis and Mann-Whitney U –Bonferroni
correction-) were evaluated. Finally, a cut-off score (Receiver Operation Curve-
ROC- analysis) was calculated using the HAMD-17 as criterion (0-7 remission).
RESULTS: In total, 305 MDD patients with a mean age (SD) of 51.75 (15.53) years
(30.5% males) were interviewed. According to the HAMD-17, 7.9% of patients were
in remission, 29.8% suffered from mild depression, 22.0% moderate depression,
21.0% severe and 19.3% very severe. Mean(SD) time for completion was 4.47(2.4)
minutes and floor or ceiling effects were found in less than 1% of patients. Cron-
bach=s  was high (0.877). Correlations with CUDOS were: -0.402(SOFAS),
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